Venmax Drugs & Pharmaceuticals opened lower at ₹14.32, compared with its previous close of ₹14.40. In the last trading session on 12 Nov 2026, the stock traded between ₹14.29 and ₹14.32, with an average traded price of ₹14.31. It showed a sideways intraday trend.
An investment of ₹10,000 made 2 years ago in Venmax Drugs & Pharmaceuticals is now worth
₹ 21,763.00
Giving a profit of
₹ 11,763.00 (117.63%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.08 (-0.56%)
Day High
₹14.32
Day Low
₹14.29
Day Open
₹14.32
Prev Close
₹14.40
Volume
1,200
Value Traded
₹0.00 Cr
1W Return
0.28%
1M Return
-0.56%
3M Return
-20.36%
6M Return
-37.79%
1Y Return
-50.60%
Market Cap (₹ Cr.)
21
PE Ratio
75.80
PB Ratio
1.00
Dividend Yield
-
ROE
1.76%
ROCE
1.96%
Book Value (₹)
14.37
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.28%
6 Weeks
-
1 Month
-0.56%
3 Months
-20.36%
9 Months
-48.80%
No data available.
Venmax Drugs shareholders approve Hatri Pharma merger with 99.99% support
Shareholders approved amalgamation with 99.99% votes in favour. Only 150 votes cast against the scheme out of 72 lakh total votes. Public shareholders voted 99.99% in favour, meeting SEBI criteria. Meeting held virtually on October 24, 2026, under NCLT directions.
17 days agoVenmax Drugs passes all 5 resolutions in 37th AGM with over 95% support
All five resolutions passed with ~95.73% votes in favour. Total valid votes cast: 64,45,797 across 92 participating members. Resolutions included FY26 financials adoption and director appointments. Merger vote with Hatri Pharma scheduled for October 24, 2026.
1mo agoVenmax Drugs to hold shareholder meeting for Hatri Pharma merger on Oct 24
NCLT Hyderabad orders Venmax Drugs to hold equity shareholder meeting on October 24, 2026. Meeting pertains to amalgamation scheme with Hatri Pharma Private Limited under Companies Act 2013. Session will be conducted via video conference at 12:30 p.m. as per tribunal directive. Case application CA (CAA) 30/230/HDB/2026 was allowed and disposed of on September 7, 2026.
2mo agoVenmax Drugs approves FY26 AGM notice, director appointments
Board approved FY26 annual report and 37th AGM notice. Venkata Rao Sadhanala appointed Managing Director with ₹30 lakh annual pay. Two additional directors regularized with no managerial remuneration. AGM scheduled for September 26, 2026 via video conferencing.
2mo agoVenmax Drugs board meets Aug 31 to approve FY26 annual report
Board meeting scheduled for August 31, 2026, at 4:30 pm. Agenda includes approval of 37th Annual Report and AGM notice. Regularization of Additional Directors' appointments to be considered. E-voting dates and Scrutinizer appointment to be finalized.
2mo agoVenmax Drugs & Pharmaceuticals Q1 Results: Unaudited financials filed
Venmax Drugs & Pharmaceuticals Limited disclosed its unaudited standalone financial results for Q1FY26, approved by the Board on August 7, 2026. The filing complies with SEBI LODR Regulations 33 and 47, with newspaper advertisements published on August 8, 2026.
3mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,898.50 | +0.72% | ₹4,55,513.74 | 41.20 | +9.61% | |
| ₹11,506.00 | +0.18% | ₹3,05,448.15 | 90.40 | +76.47% | |
| ₹4,689.50 | -0.80% | ₹1,78,373.51 | 85.50 | +22.61% | |
| ₹2,434.80 | +1.45% | ₹1,31,555.22 | 97.10 | +146.13% | |
| ₹1,204.60 | -0.12% | ₹1,20,159.31 | 28.00 | +26.61% | |
| ₹1,389.60 | +0.22% | ₹1,15,987.17 | 42.00 | +13.01% | |
| ₹1,409.00 | +0.05% | ₹1,13,827.26 | 39.90 | -7.26% | |
| ₹2,666.70 | +1.06% | ₹1,10,146.73 | 48.10 | +17.48% | |
| ₹1,815.40 | +0.45% | ₹1,04,454.10 | 26.00 | +53.38% | |
| ₹2,020.80 | +0.29% | ₹92,409.16 | 17.60 | -0.64% | |
| ₹2,643.30 | -0.62% | ₹74,600.45 | 51.60 | +43.05% | |
| ₹5,190.00 | -2.11% | ₹62,054.24 | 30.50 | -10.01% |
An investment of ₹10,000 made 2 years ago in Venmax Drugs & Pharmaceuticals is now worth
₹ 21,763.00
Giving a profit of
₹ 11,763.00 (117.63%)
Note: Past profits do not guarantee future returns.
